Literature DB >> 3790406

Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate.

D J Morgan, J D Paull, B H Richmond, E Wilson-Evered, S P Ziccone.   

Abstract

The pharmacokinetics of salbutamol and its sulphate conjugate metabolite were investigated after intravenous and steady-state oral administration of salbutamol to 10 healthy volunteers. With intravenous administration, total plasma clearance was 480 +/- 123 ml min-1, elimination half-life was 3.86 +/- 0.83 h and apparent volume of distribution was 156 +/- 381. Urinary excretion of unchanged drug and sulphate conjugate were 64.2 +/- 7.1% and 12.0 +/- 3.1% of the dose, respectively. With oral administration, systemic availability was 0.50 +/- 0.04, and urinary excretion of unchanged drug and sulphate conjugate were 31.8 +/- 1.9% and 48.2 +/- 7.3% of the dose, respectively. The drug eliminated on the first-pass could be accounted for entirely as sulphate conjugate formed, presumably, in the intestinal wall. Renal clearance of salbutamol was 291 +/- 70 ml min-1 after intravenous and 272 +/- 38 ml min-1 after oral administration, while the renal clearance of the sulphate conjugate was 98.5 +/- 23.5 ml min-1 after oral administration. Heart rate increased with increasing plasma salbutamol concentration, although a lag was evident. The effect on heart rate was lower after 24 h continuous oral salbutamol administration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3790406      PMCID: PMC1401185          DOI: 10.1111/j.1365-2125.1986.tb02939.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  The clinical pharmacology of oral and inhaled salbutamol.

Authors:  S R Walker; M E Evans; A J Richards; J W Paterson
Journal:  Clin Pharmacol Ther       Date:  1972 Nov-Dec       Impact factor: 6.875

2.  Metabolic studies of Salbutanol-3H: a new bronchodilator, in rat, rabbit, dog and man.

Authors:  L E Martin; J C Hobson; J A Page; C Harrison
Journal:  Eur J Pharmacol       Date:  1971-04       Impact factor: 4.432

3.  Cardiovascular consequences of beta-agonist tocolysis: an echocardiographic study.

Authors:  J Finley; M Katz; M Rojas-Perez; J M Roberts; R K Creasy; N B Schiller
Journal:  Obstet Gynecol       Date:  1984-12       Impact factor: 7.661

4.  Absorption, excretion and urinary metabolic pattern of 3 H-albuterol aerosol in man.

Authors:  C Lin; J Magat; B Calesnick; S Symchowicz
Journal:  Xenobiotica       Date:  1972-11       Impact factor: 1.908

5.  The metabolism of salbutamol in man.

Authors:  M E Evans; S R Walker; R T Brittain; J W Paterson
Journal:  Xenobiotica       Date:  1973-02       Impact factor: 1.908

6.  Pharmacokinetics of triamterene and its metabolite in man.

Authors:  J Hasegawa; E T Lin; R L Williams; F Sörgel; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

7.  Drug metabolism by the gastrointestinal mucosa.

Authors:  C F George
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

8.  Slow-release oral salbutamol and aminophylline in nocturnal asthma: relation of overnight changes in lung function and plasma drug levels.

Authors:  A J Fairfax; W R McNabb; H J Davies; S G Spiro
Journal:  Thorax       Date:  1980-07       Impact factor: 9.139

9.  Comparative bioavailability and pharmacokinetics of three formulations of albuterol.

Authors:  M L Powell; M Weisberger; R Gural; M Chung; J E Patrick; E Radwanski; S S Symchowicz
Journal:  J Pharm Sci       Date:  1985-02       Impact factor: 3.534

10.  Renal clearance and serum protein binding of acetaminophen and its major conjugates in humans.

Authors:  M E Morris; G Levy
Journal:  J Pharm Sci       Date:  1984-08       Impact factor: 3.534

View more
  52 in total

1.  Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man--no evidence of enantioselective lung metabolism.

Authors:  J K Ward; J Dow; N Dallow; P Eynott; S Milleri; G P Ventresca
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

2.  Determination of the relative bioavailability of salbutamol to the lung following inhalation.

Authors:  M Hindle; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

3.  Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma.

Authors:  B J Lipworth; R A Clark; D P Dhillon; J B Palmer; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration.

Authors:  G Hochhaus; E W Schmidt; K L Rominger; H Möllmann
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

5.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

6.  Beta2-Agonist Doping Control and Optical Isomer Challenges.

Authors:  Glenn A Jacobson; J Paul Fawcett
Journal:  Sports Med       Date:  2016-12       Impact factor: 11.136

7.  The effect of oral salbutamol on cation transport measured in vivo in healthy volunteers.

Authors:  A J Wood; C J Brearley; J K Aronson; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

8.  Stereoselective metabolism of RS-albuterol in humans.

Authors:  T Walle; E A Eaton; U K Walle; G R Pesola
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

9.  Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity.

Authors:  U K Walle; G R Pesola; T Walle
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

10.  Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.

Authors:  Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.